Abstract
Aim Ciclosporin (CsA) has been shown to follow nonlinear pharmacokinetics in renal transplant recipients who received Neoral-based triple immunosuppressive therapy. Some of these nonlinear properties have not been fully considered in population pharmacokinetic (popPK) analysis. Therefore, the aim of this study was to determine the potential influence of nonlinearity and the functional forms of covariates on model predictability.
Methods A total of 2969 CsA whole-blood measurements, including 1328 pre-dose and 1641 2-h post-dose concentrations, were collected from 173 patients who underwent their first renal transplantation. Four popPK models based on different modelling strategies were developed to investigate the discrepancy between empirical and theory-based, linear and nonlinear compartmental kinetic models and empirical formulae on model predictability. Prediction-based and simulation-based diagnostics (prediction-corrected visual predictive checks) were performed to determine the stability and predictive performance of these four models.
Results Model predictability improved when nonlinearity was considered. The theory-based nonlinear model which incorporated nonlinear property based on known theoretical relationships performed better than the other two compartmental models. The nonlinear Michaelis-Menten model showed a remarkable improvement in predictive performance over that of the other three compartmental models. The saturated binding of CsA to erythrocytes, and auto-inhibition that arose from the inhibitory effects of CsA on CYP3A4/P-gp and CsA-prednisolone drug interaction may have contributed to the nonlinearity.
Conclusions Incorporating nonlinear properties are likely to be a promising approach for improving CsA model predictability. However, CsA nonlinear kinetics resources need further investigation. Until then, Michaelis-Menten empirical model can be used for CsA dose adjustments.
What is already known about this subject
CsA in renal transplant recipients receiving Neoral-based triple immunosuppressive therapy followed nonlinear pharmacokinetics.
Nonlinearity is rarely incorporated into CsA population pharmacokinetic (popPK) modelling processes.
What this study adds
Four popPK models based on different modelling strategies were developed to investigate the discrepancy between empirical and theory-based compartmental kinetic models and empirical formulae, as well as the effect of nonlinearity on CsA model predictability.
Based on the four models, incorporating nonlinear properties is likely to be a promising approach for improving CsA model predictability.
Saturated distribution into red blood cells, and auto-inhibition that arose from the inhibitory effects of CsA on CYP3A4/P-gp and CsA-prednisolone drug interaction may be the main sources of CsA PK nonlinearity.
Principal Investigator statement The authors confirm that the Principal Investigator for this paper is Zheng Jiao and that he had direct clinical responsibility for patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is a retrospective study to analyze the routine clinical data. It was approved by the ethnic committee of Huashan Hospital.
Funding Statement
This work was supported in part by grants from the National Natural Science Foundation of China (No. 81 573 505 and 81 072 702), the “2016 Key Clinical Program of Clinical Pharmacy”, and “Weak Discipline Construction Project” (No. 2016ZB0301-01) of Shanghai Municipal Health and Family Planning Commission
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
